Pharma & Life Sciences

Medline Recalls Namic Angiographic Syringes Over Unwinding Risk

Medline Industries issued an urgent medical device recall for Namic Angiographic Rotating Adaptor (RA) Control Syringes and Convenience Kits after identifying that the syringe rotating adaptor may unwind during use, causing loose connections or full disconnection from the manifold. The FDA has classified this as the most serious recall type due to the risk of biohazard exposure, blood loss, infection, air embolism, serious injury, or death. Four serious injuries have been reported as of March 13.

Baxter Volara Single-Patient Use Circuits - Updated Instructions, Class I Recall

FDA announced a Class I recall correction for Baxter Volara single-patient use ventilator circuits after reports of oxygen desaturation and barotrauma risks. The affected Blue Ventilator Adaptor Module (Product Code M07937) may cause serious injury or death when used in-line with home care ventilators without following updated instructions. Baxter is notifying affected customers and providing clinical support including in-home training visits.

Ketamine and NAP patent for ADNP syndrome treatment

Ketamine and NAP patent for ADNP syndrome treatment

N-Acetyl Leucine Treats Niemann-Pick Disease Type C with NPC1 Mutations

The USPTO published patent application US20260097008A1 by inventor Michael Strupp covering methods of treating Niemann-Pick Disease Type C (NPC) or neurological symptoms thereof by administering N-acetyl leucine to subjects carrying NPC1 mutations. The application (No. 19352209) was filed October 7, 2025, and published April 9, 2026.

Adagrasib mTOR Inhibitor Combination Cancer Treatment

USPTO published patent application US20260097038A1 by Mirati Therapeutics covering combination therapies using Adagrasib (KRas G12C inhibitor) with mTOR inhibitors for treating KRas G12C mutant cancers. The application discloses methods of treatment, pharmaceutical compositions, and kits comprising therapeutically effective amounts of both inhibitors.

Prostate Cancer Combination Therapy, Abiraterone Acetate, Niraparib

USPTO published patent application US20260097048A1 for a combination therapy of abiraterone acetate and niraparib for treating prostate cancer. The application was filed on December 11, 2025, by inventors Thomas Ronald A. Quinten and colleagues, covering free-dose and fixed-dose combinations and methods of treatment.

Pharmaceutical Composition Comprising Enavogliflozin for Cardiovascular Aging Diseases

The USPTO published patent application US20260097060A1 for a pharmaceutical composition comprising enavogliflozin as an active ingredient for preventing or treating cardiovascular aging diseases. The invention demonstrates effects in preventing endothelial dysfunction caused by vascular endothelial senescence. The application was filed on September 27, 2023, under Application No. 19115424.

Methods Of Treating Fabry Patients Having Renal Impairment

USPTO published patent application US20260097027A1 by Amicus Therapeutics Inc. covering methods of treating Fabry disease in patients with renal impairment. The application claims administering migalastat hydrochloride at about 150 mg every other day to patients with HEK assay amenable mutations in α-galactosidase A.

Compositions and Methods for Activating GLP-1 Secretion via Nutritional Supplements

USPTO published patent application US20260096587A1 for nutritional supplement compositions designed to activate GLP-1 peptide secretion to regulate blood sugar, weight, and hunger. The application covers formulations combining hydrolyzed yeast, acacia gum, citrus bioflavonoids, cinnamon bark, MCTs, resistant starches, and botanical extracts, with disclosed efficacy of up to 200% increase in GLP-1 production. Inventors include Elisa Diane Barnes, Christina Beer, Clinton T. Horton, and Robert A. Carr.

M13 Phage Engineered to Capture SARS-CoV-2 Virus

M13 Phage Engineered to Capture SARS-CoV-2 Virus